Clinical trials: in Croatia
Mycobacterium Avium Complex Pulmonary Disease
A Prospective, Multicenter, Single-arm MAC-PD Cohort: a NTM-NET and ESGMYC Collaborative Study
To gain insight in the effectiveness of, adherence and adjustments to guideline-based three-drug antimycobacterial therapy in patients with Mycobacterium avium complex pulmonary disease (MAC-PD) during the first 6 months of…
- Trial name
- MAC-PD cohort (NCT05906316)
- Where
- 11 sites in United States, Belgium and 8 more
- Volunteers
- 100 people
- Sponsor
- Radboud University Medical Center
Agitation, Alzheimer's Type Dementia
Masupirdine for the Treatment of Agitation in Dementia of the Alzheimer's Type
This study will be conducted to evaluate the efficacy, safety, tolerability, and pharmacokinetics of masupirdine compared to placebo for the treatment of agitation in participants with dementia of the Alzheimer's type.
- Trial name
- NCT05397639
- Testing
- Masupirdine 50 mg, Masupirdine 100 mg
- Where
- 44 sites in United States, Croatia and 2 more
- Volunteers
- 375 people
- Sponsor
- Suven Life Sciences Limited
Schizophrenia
A Study for Participants With Schizophrenia
The purpose of this study is to test the hypothesis that 1 or more dose levels of LY2140023 given orally to participants with schizophrenia twice daily for 4 weeks will have significantly greater effect than placebo.
- Trial name
- NCT00520923
- Testing
- LY2140023, Olanzapine
- Where
- 35 sites in Argentina, Austria and 7 more
- Volunteers
- 669 people
- Sponsor
- Denovo Biopharma LLC
Moderately to Severely Active Ulcerative Colitis
A Study to Assess the Efficacy and Safety of Afimkibart (Also Known as RO7790121) for Induction and Maintenance Therapy in Participants With Moderately to Severely Active Ulcerative Colitis
This Phase III, multicenter, double-blind, placebo-controlled, treat-through study will evaluate the efficacy and safety of Afimkibart (RO7790121) compared with placebo in participants with moderately to severely active…
- Trial name
- Ametrine-1 (NCT06589986)
- Testing
- Afimkibart
- Where
- 184 sites in United States, Argentina and 28 more
- Volunteers
- 400 people
- Sponsor
- Hoffmann-La Roche
Schizophrenia
A Comparator Study of LY2140023 Versus Placebo in Schizophrenia Patients
An inpatient/outpatient study to see if LY2140023 is better than placebo in acutely ill patients with schizophrenia.
- Trial name
- NCT01086748
- Testing
- Risperidone, LY2140023
- Where
- 28 sites in United States, Croatia and 1 more
- Volunteers
- 1,134 people
- Sponsor
- Denovo Biopharma LLC
Schizophrenia
A Long-Term, Open-Label, Study on Schizophrenia
The primary purpose of the study is to help answer the following research questions: How LY 2140023 can be tolerated by patients with Schizophrenia compared to standard of care treatment in 52 weeks time period.
- Trial name
- NCT01129674
- Testing
- LY2140023, Olanzapine, Aripiprazole
- Where
- 81 sites in United States, Croatia and 7 more
- Volunteers
- 560 people
- Sponsor
- Denovo Biopharma LLC
Diabetes Mellitus, Type 2
A Research Study Comparing How Well Different Doses of the Medicine NNC0662-0419 Lower Blood Sugar in People With Type 2 Diabetes
This study is being done to look at the effect and safety of different doses of NNC0662-0419 in people living with type 2 diabetes when compared to placebo or semaglutide.
- Trial name
- NCT07415954
- Testing
- NNC0662-0419, Semaglutide
- Where
- 63 sites in United States, Croatia and 8 more
- Volunteers
- 270 people
- Sponsor
- Novo Nordisk A/S
Diffuse Large B-Cell Lymphoma
A Study to Evaluate Change in Disease Activity of Subcutaneous (SC) Epcoritamab Combined With Intravenous and Oral Rituximab, Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine, and Prednisone (R-CHOP) or R-CHOP in Adult Participants With Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)
B-cell Lymphoma is an aggressive and rare cancer of a type of immune cells (a white blood cell responsible for fighting infections).
- Trial name
- EPCORE DLBCL-2 (NCT05578976)
- Testing
- Epcoritamab, Cyclophosphamide, Rituximab
- Where
- 331 sites in United States, Australia and 29 more
- Volunteers
- 900 people
- Sponsor
- Genmab
Cardiomyopathy, Secondary, Arrhythmias, Cardiac
Pacing Advancements With Cost and Experience VALuation for Unified Patient-Led Clinical Evidence - the PACEVALUE Study
The PACEVALUE study is a large, international observational study aiming to improve the treatment of patients receiving cardiac implantable electronic devices (CIEDs) such as pacemakers, implantable cardioverter-defibrillators…
- Conditions
- Cardiomyopathy, Secondary, Arrhythmias, Cardiac, Heart Failure, Pacing Induced Cardiomyopathy
- Trial name
- PACEVALUE (NCT07276139)
- Where
- 13 sites in Australia, Bulgaria and 5 more
- Volunteers
- 4,500 people
- Sponsor
- Insel Gruppe AG, University Hospital Bern
Trauma (Including Fractures)
Stress in Trauma Patients in Triage Categories 3-5
The aim of this study is to better understand what causes patients the most concern immediately after an injury. We would like to find out how stressed patients are and whether the main causes of stress are pain, fear regarding…
- Trial name
- NCT07811830
- Testing
- Questionnaire and Physical Exam
- Where
- Croatia
- Volunteers
- 300 people
- Sponsor
- Gabriela Katharina Pomper
Hereditary Angioedema, HAE
STOP-HAE: A Phase 3 Study of ADX-324 in HAE
This study will evaluate the efficacy and safety of ADX-324 in participants with Type 1 or Type 2 hereditary angioedema. The study will also evaluate safety, pharmacokinetics (PK), pharmacodynamics (PD), and health-related…
- Conditions
- Hereditary Angioedema, HAE, Hereditary Angioedema - Type 1, Hereditary Angioedema - Type 2
- Trial name
- STOP-HAE (NCT06960213)
- Testing
- ADX-324
- Where
- 70 sites in United States, Argentina and 22 more
- Volunteers
- 90 people
- Sponsor
- ADARx Pharmaceuticals, Inc.
Ulcerative Colitis
ABTECT-2 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -2
This is a multicenter, randomized, placebo controlled study to evaluate the efficacy and safety of ABX464 given at 25 or 50 mg QD in inducing clinical remission in subjects with moderately to severely active ulcerative colitis…
- Trial name
- NCT05507216
- Testing
- ABX464
- Where
- 262 sites in United States, Argentina and 25 more
- Volunteers
- 636 people
- Sponsor
- Abivax S.A.
Ventilator Associated Pneumonia
Perpetual Observational Study - Ventilator Associated Pneumonia
Ventilator-Associated Pneumonia (VAP) is a bacterial respiratory infection that patients in the Intensive Care Unit (ICU) often get when they cannot breathe for themselves and require mechanical ventilation.
- Trial name
- POS-VAP (NCT05719259)
- Where
- 35 sites in Albania, Belgium and 11 more
- Volunteers
- 20,000 people
- Sponsor
- European Clinical Research Alliance for Infectious Diseases (ECRAID)
Genetic Disease, Immune Dysfunction
Natural History of Type 1 Interferonopathies: Insights From a European Cohort
Type I interferonopathies are rare autoinflammatory disorders caused by genetic defects and associated with significant morbidity and mortality. These diseases are refractory to conventional immunosuppressive therapies.
- Conditions
- Genetic Disease, Immune Dysfunction, Neurological Diseases or Conditions, Autoimmune Diseases
- Trial name
- EU-IFNp (NCT07040774)
- Where
- 32 sites in Austria, Belgium and 9 more
- Volunteers
- 500 people
- Sponsor
- Imagine Institute
Acute Pyelonephritis, Complicated Urinary Tract Infection
A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Meropenem-Vaborbactam in Children With Complicated Urinary Tract Infection, Including Acute Pyelonephritis
The primary objective of the study is to assess the safety and tolerability of meropenem-vaborbactam administered by intravenous (IV) infusion in children 3 months and above to less than 12 years with complicated urinary tract…
- Trial name
- NCT06672978
- Testing
- Meropenem-Vaborbactam, Antibiotics
- Where
- 26 sites in United States, Bulgaria and 4 more
- Volunteers
- 66 people
- Sponsor
- Rempex (a wholly owned subsidiary of Melinta Therapeutics, LLC)
Heart Failure, Acute Heart Failure
A Study to Determine the Efficacy and Safety of Finerenone on Morbidity and Mortality Among Hospitalized Heart Failure Patients
Finerenone will be compared to placebo to determine efficacy and safety of treatment in patients hospitalized with acute decompensated heart failure (HF) and mildly reduced or preserved left ventricular ejection fraction.
- Trial name
- REDEFINE-HF (NCT06008197)
- Testing
- Finerenone
- Where
- 356 sites in United States, Argentina and 24 more
- Volunteers
- 5,200 people
- Sponsor
- Colorado Prevention Center
Triple Negative Breast Neoplasms
Study Assessing the Efficacy and Safety of Alpelisib + Nab-paclitaxel in Subjects With Advanced TNBC Who Carry Either a PIK3CA Mutation or Have PTEN Loss
The purpose of this study was to determine whether treatment with alpelisib in combination with nab-paclitaxel is safe and effective in subjects with advanced triple negative breast cancer (aTNBC) who carry either a PIK3CA…
- Trial name
- EPIK-B3 (NCT04251533)
- Testing
- alpelisib, nab-paclitaxel
- Where
- 78 sites in United States, Argentina and 28 more
- Volunteers
- 137 people
- Sponsor
- Novartis Pharmaceuticals
Patellofemoral Osteoarthritis
Treatment of Patellofemoral Osteoarthritis With Engineered Cartilage.
The purpose of this investigator-initiated study is to assess the efficacy of treating patellofemoral osteoarthritis with an Advanced Therapy Medicinal Product (ATMP), autologous nasal chondrocyte tissue engineered cartilage…
- Trial name
- NCT06163573
- Testing
- N-TEC, Platelet rich plasma
- Where
- 9 sites in Croatia, Germany and 1 more
- Volunteers
- 75 people
- Sponsor
- University Hospital, Basel, Switzerland
Haemophilia A With Inhibitors, Haemophilia B With Inhibitors
Research Study to Look at How Well the Drug Concizumab Works in Your Body if You Have Haemophilia With Inhibitors
This study will test how well a new medicine called concizumab works in the body of people with haemophilia A or B with inhibitors. The purpose is to show that concizumab can prevent bleeds in the body and is safe to use.
- Trial name
- explorer7 (NCT04083781)
- Testing
- Concizumab
- Where
- 99 sites in United States, Algeria and 27 more
- Volunteers
- 134 people
- Sponsor
- Novo Nordisk A/S
Psoriatic Arthritis
Continuation Study of Zasocitinib in Adults With Psoriatic Arthritis
Psoriatic arthritis (PsA) is a long-term inflammatory disease that affects the joints and skin. The purpose of this study is to check how safe zasocitinib is, how well it is tolerated and how well it works in adults with PsA over…
- Trial name
- NCT07286058
- Testing
- Zasocitinib
- Where
- 78 sites in United States, Australia and 14 more
- Volunteers
- 1,182 people
- Sponsor
- Takeda
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.